机构:[1] Guangzhou Univ Chinese Med, Clin Med Coll 2, Sect Immunol, Guangzhou 510006, Guangdong, Peoples R China; Guangzhou Univ Chinese Med, Clin Med Coll 2, Joint Immunol Program, Guangzhou 510006, Guangdong, Peoples R China; Guangdong Prov Acad Chinese Med Sci, Guangzhou 510006, Guangdong, Peoples R China
Traditional Chinese Medicine (TCM) has been traditionally used to treat patients with cancers in China. It not only alleviates the symptoms of tumor patients and improves their quality of life, but also controls the size of tumors and prolongs the survival of tumor patients. While some herbs of TCM may exert therapeutic effects by directly targeting cancer cells or reducing side effects caused by antitumor drugs, others can control tumor growth and metastasis via enhancing antitumor immunity. In particular, TCM can exert antitumor effects by upregulating immune responses even in immunosuppressive tumor microenvironment. For instance, it reduces the number of M2-type macrophages and Treg cells in the tumor tissue. Although extensive reviews on directly killing cancer cells by TCM have been conducted, a review of anticancer activity of TCM solely based on its immunity-enhancing capacity is unusual. This review will summarize research progress of antitumor TCM that regulates the immune system, including both innate immunity, such as macrophages, dendritic cells, natural killer cells and MDSCs, and adaptive immunity, including CD4(+)/CD8(+) T lymphocytes, regulatory T cells (Tregs) and B cells. As cancer immunotherapy has recently achieved certain success, it is expected that the clinical applications of immunity-enhancing TCM or traditional medicine for treating various cancer patients will be expanded. Further studies on the mechanisms by which TCM regulates immunity will provide new insights into how TCM controls tumor growth and metastasis, and may help improve its therapeutic effects on various cancers in clinic.
基金:
Specific Research Funds for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine, China [YN2016ZD01, YN2018ZD08, YN2019MJ03]
语种:
中文
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类|3 区医学
小类|3 区医学:研究与实验3 区药学
最新[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
JCR分区:
出版当年[2018]版:
Q1PHARMACOLOGY & PHARMACYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构:[1] Guangzhou Univ Chinese Med, Clin Med Coll 2, Sect Immunol, Guangzhou 510006, Guangdong, Peoples R China; Guangzhou Univ Chinese Med, Clin Med Coll 2, Joint Immunol Program, Guangzhou 510006, Guangdong, Peoples R China; Guangdong Prov Acad Chinese Med Sci, Guangzhou 510006, Guangdong, Peoples R China
通讯作者:
通讯机构:[*1]Guangzhou Univ Chinese Med, Clin Med Coll 2, Sect Immunol, Guangzhou 510006, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
Wang Yeshu,Zhang Qunfang,Chen Yuchao,等.Antitumor effects of immunity-enhancing traditional Chinese medicine[J].BIOMEDICINE & PHARMACOTHERAPY.2020,121: